Hyderabad-based Bharat Biotech has signed a deal with the Thomas Jefferson University in Philadelphia to develop a vaccine candidate for Covid-19. The vaccine called Coravax was developed at Jefferson using an existing deactivated rabies vaccine as a carrier for coronavirus proteins. It has recently completed preliminary trials in animal models. The data on whether it protects vaccinated animals against Covid-19 is expected next month. The firm aims to begin human trials as early as December. Through the partnership, the two aim to accelerate the vaccine candidate through the next phases of development.